Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Lee, Jung Eun ^a,b,c   Gohda, Tomohito ^a,c,d   Walker, William H ^a   Skupien, Jan ^a,c,e   Smiles, Adam M ^a   Holak, Rita R ^a   Jeong, Jackson ^a   McDonnell, Kevin P ^a   Krolewski, Andrzej S ^a,c   Niewczas, Monika A ^a,c  

^a JOSLIN DIABETES CENTER   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ALBUMINURIA; ARTICLE; DEATH; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MASSACHUSETTS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RISK FACTORS;

EID: 84875136999     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058007     Document Type: Article

References (39)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, et al. (2012) United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 59: A7, e1-A7,420.
2. McEwen LN, Karter AJ, Waitzfelder BE, Crosson JC, Marrero DG, et al. (2011) Predictors of Mortality Over 8 Years in Type 2 Diabetic Patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care pp. dc11-2281.
3. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, et al. (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348: 2285-2293.
4. MacIsaac RJ, Jerums G, (2011) Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 20: 246-257.
5. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, et al. (2007) Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772.
6. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, et al. (2012) Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. J Am Soc Nephrol 23: 516-524.
7. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, et al. (2012) Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. J Am Soc Nephrol 23: 507-515.
8. Aderka D, (1996) The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 7: 231-240.
9. Levine SJ, (2008) Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 283: 14177-14181.
10. Prie D, Friedlander G, (2010) Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol 5: 1717-1722.
11. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, et al. (2003) Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 278: 2206-2211.
12. Baum M, Schiavi S, Dwarakanath V, Quigley R, (2005) Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 68: 1148-1153.
13. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, et al. (2011) FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922.
14. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, et al. (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608.
15. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, et al. (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592.
16. Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, et al. (2011) FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 6: 241-247.
17. Isakova T, Xie H, Yang W, Xie D, Anderson AH, et al. (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439.
18. Krieger NS, Culbertson CD, Kyker-Snowman K, Bushinsky DA, (2012) Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am J Physiol Renal Physiol 303: F431-F436.
19. Mendoza JM, Isakova T, Ricardo AC, Xie H, Navaneethan SD, et al. (2012) Fibroblast Growth Factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 7: 1155-1162.
20. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, et al. (2011) Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22: 1144-1151.
21. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH, (1995) Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332: 1251-1255.
22. Agodoa LY, Eggers PW, (1995) Renal replacement therapy in the United States: data from the United States Renal Data System. Am J Kidney Dis 25: 119-133.
23. Centers for Disease Control and Prevention, National Center for Health Statistics website. Avaiable: http://www.cdc.gov/nchs/ndi.htm. Accessed 2010 Oct 10.
24. Gooley TA, Leisenring W, Crowley J, Storer BE, (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18: 695-706.
25. Bergstralh E: SAS Macro That Performs Cumulative Incidence in Presence of Completing Risks. Available: http://mayoresearch.mayo.edu/mayo/research/biostat/upload/comprisk.sas. Accessed 2010 Feb 3.
26. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB, (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279.
27. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, et al. (2004) Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 29: 91-99.
28. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, et al. (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123.
29. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, et al. (2001) Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 280: 1015-1020.
30. Bernheim J, Benchetrit S, (2011) The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant 26: 2433-2438.
31. Moreno JA, Izquierdo MC, Sanchez-Nino MD, Suarez-Alvarez B, Lopez-Larrea C, et al. (2011) The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J Am Soc Nephrol 22: 1315-1325.
32. Zhao Y, Banerjee S, Dey N, LeJeune WS, Sarkar PS, et al. (2011) Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes 60: 1907-1916.
33. Seiler S, Wen M, Roth HJ, Fehrenz M, Flugge F, et al. (2012) Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 10.1038/ki.2012.288 [doi].
34. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, et al. (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52: 249-255.
35. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435.
36. Shab-Bidar S, Neyestani TR, Djazayery A, Eshraghian MR, Houshiarrad A, et al. (2012) Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev 28: 424-430.
37. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, et al. (2010) FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78: 679-685.
38. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, et al. (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119: 2545-2552.
39. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, et al. (2010) Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95: 578-585.